Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$27.68
$1.05(3.79%)
At close: 4:00 PM EDT
$27.68
$1.05(3.79%)
Day’s Range― - ―
52-Week Range$12.91 - $53.65
Previous CloseN/A
Volume102.86K
Average Volume (3M)698.25K
Market Cap
$1.65B
Enterprise Value$1.41K
Total Cash (Recent Filing)$411.09M
Total Debt (Recent Filing)$60.42M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 05, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding55,549,168
10 Day Avg. Volume397,036
30 Day Avg. Volume698,254
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$66.25Price Target Upside139.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.76
Revenue Forecast (FY)$22.00M
Bulls Say, Bears Say
Bulls Say
Strong Equity BaseThe sizable equity base and low leverage provide financial flexibility for continued clinical development. This capital cushion can help Maze fund research programs and manage volatility without relying immediately on substantial additional borrowing.
Clinical Pipeline ProgressAdvancement of MZE782 and MZE829 into later-stage trials creates multiple potential value drivers and supports a longer development horizon. The stated runway into 2029 improves the company’s ability to reach clinical milestones before needing new capital.
Precision Medicine PlatformA genetically informed discovery model can improve target selection and patient stratification, potentially increasing development efficiency and clinical differentiation. This platform approach may support a broader pipeline rather than dependence on a single therapeutic candidate.
Bears Say
Large Ongoing LossesThe large loss relative to current revenue shows that operating expenses materially exceed the company’s present commercial or collaboration income. Unless clinical progress translates into partnerships, approvals, or product revenue, profitability remains a distant and uncertain objective.
Persistent Cash BurnSustained cash outflows reduce the company’s financial resources while its pipeline remains in development. Even with an extended stated runway, continued burn could eventually require financing, collaboration economics, or spending reductions that may affect development pace.
Unstable Revenue And ReturnsThe sharp revenue swings indicate limited recurring revenue visibility and dependence on irregular business activity or collaborations. Negative returns on equity also show that the current capital base is not yet generating economic returns, increasing execution risk.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $12.91 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.65B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.043.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.76.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,549,168 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.25 (139.34% Upside)
$66.25 (139.34% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 214.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.15%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$66.25
▲(139.34% Upside)
Technical Analysis
Intellia Therapeutics
―
Damora Therapeutics
―
Recursion Pharmaceuticals
―
Ginkgo Bioworks Holdings
―
Generate Biomedicines, Inc.
―
Ownership Overview
10.98% Insiders
5.50% Mutual Funds
68.30% Other Institutional Investors
6.37% Public Companies and
Individual Investors